SEC Comment Letter for Entero Therapeutics, Inc. (GRDX) (CIK 0001604191) (GRDX) — Jul 27, 2017
Entero Therapeutics, Inc. (GRDX) (CIK 0001604191)
Date: July 27, 2017 · CIK: 0001604191 · Accession: 0000000000-17-026399
AI Filing Summary & Sentiment
Reasoning
Letter
July 27, 2017 Johan Spoor President and Chief Executive Officer AzurRx BioPharma, Inc. 760 Parkside Avenue Downstate Biotechnology Incubator, Suite 304 Brooklyn, NY 11226 AzurRx BioPharma, Inc. Registration Statement on Form S-1 Filed July 21, 2017 File No. 333-219385Re: Dear Mr. Spoor: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dorrie Yale at 202-551-8776 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Jessica R. Sudweeks
Show Raw Text
July 27, 2017 Johan Spoor President and Chief Executive Officer AzurRx BioPharma, Inc. 760 Parkside Avenue Downstate Biotechnology Incubator, Suite 304 Brooklyn, NY 11226 AzurRx BioPharma, Inc. Registration Statement on Form S-1 Filed July 21, 2017 File No. 333-219385Re: Dear Mr. Spoor: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dorrie Yale at 202-551-8776 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Jessica R. Sudweeks